A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 697 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions May 18, 2020 Pink Speed Bump Reminds Drivers to Schedule Their Yearly Mammograms November 1, 2019 Five Questions With…Fern, Christina, Mary, and Shelley. May 26, 2022 Some Brain Cells May Help to Fuel Cancer Metastasis November 21, 2019 Load more HOT NEWS Biosimilars for Cancer Emerge as Patents on Widely Used Biological Drugs... Get the Most out of Seasonal Fruits! Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast... Checking in on our Mental Health
